Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.
Zarogoulidis P, Huang H, Tsiouda T, Sardeli C, Trakada G, Veletza L, Kallianos A, Kosmidis C, Rapti A, Papaemmanouil L, Hatzibougias D, Drougas D, Bai C, Hohenforst-Schmidt W.
Zarogoulidis P, et al. Among authors: bai c.
Respir Med Case Rep. 2017 Oct 26;22:283-286. doi: 10.1016/j.rmcr.2017.10.006. eCollection 2017.
Respir Med Case Rep. 2017.
PMID: 29124007
Free PMC article.